IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v7y2016i1d10.1038_ncomms11253.html
   My bibliography  Save this article

CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia

Author

Listed:
  • Kelly L. Williams

    (Faculty of Medicine and Health Sciences, Macquarie University
    Northcott Neuroscience Laboratory, ANZAC Research Institute
    Sydney Medical School, University of Sydney)

  • Simon Topp

    (Medical Research Council Centre for Neurodegeneration Research, Institute of Psychiatry, King’s College London)

  • Shu Yang

    (Faculty of Medicine and Health Sciences, Macquarie University
    Northcott Neuroscience Laboratory, ANZAC Research Institute)

  • Bradley Smith

    (Medical Research Council Centre for Neurodegeneration Research, Institute of Psychiatry, King’s College London)

  • Jennifer A. Fifita

    (Faculty of Medicine and Health Sciences, Macquarie University
    Northcott Neuroscience Laboratory, ANZAC Research Institute)

  • Sadaf T. Warraich

    (Faculty of Medicine and Health Sciences, Macquarie University)

  • Katharine Y. Zhang

    (Faculty of Medicine and Health Sciences, Macquarie University)

  • Natalie Farrawell

    (Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong)

  • Caroline Vance

    (Medical Research Council Centre for Neurodegeneration Research, Institute of Psychiatry, King’s College London)

  • Xun Hu

    (Medical Research Council Centre for Neurodegeneration Research, Institute of Psychiatry, King’s College London)

  • Alessandra Chesi

    (Stanford University School of Medicine)

  • Claire S. Leblond

    (Montreal Neurological Institute and Hospital, McGill University
    Montreal University)

  • Albert Lee

    (Faculty of Medicine and Health Sciences, Macquarie University
    Australian Proteome Analysis Facility, Macquarie University)

  • Stephanie L. Rayner

    (Faculty of Medicine and Health Sciences, Macquarie University)

  • Vinod Sundaramoorthy

    (Faculty of Medicine and Health Sciences, Macquarie University
    La Trobe University)

  • Carol Dobson-Stone

    (Neuroscience Research Australia, Randwick
    School of Medical Sciences, University of New South Wales, Kensington)

  • Mark P. Molloy

    (Faculty of Medicine and Health Sciences, Macquarie University
    Australian Proteome Analysis Facility, Macquarie University)

  • Marka van Blitterswijk

    (Mayo Clinic Florida)

  • Dennis W. Dickson

    (Mayo Clinic Florida)

  • Ronald C. Petersen

    (Mayo Clinic Rochester)

  • Neill R. Graff-Radford

    (Mayo Clinic Florida)

  • Bradley F. Boeve

    (Mayo Clinic Rochester)

  • Melissa E. Murray

    (Mayo Clinic Florida)

  • Cyril Pottier

    (Mayo Clinic Florida)

  • Emily Don

    (Faculty of Medicine and Health Sciences, Macquarie University)

  • Claire Winnick

    (Faculty of Medicine and Health Sciences, Macquarie University)

  • Emily P. McCann

    (Faculty of Medicine and Health Sciences, Macquarie University)

  • Alison Hogan

    (Faculty of Medicine and Health Sciences, Macquarie University)

  • Hussein Daoud

    (Montreal Neurological Institute and Hospital, McGill University
    Montreal University)

  • Annie Levert

    (Montreal Neurological Institute and Hospital, McGill University
    Montreal University)

  • Patrick A. Dion

    (Montreal Neurological Institute and Hospital, McGill University
    Montreal University)

  • Jun Mitsui

    (Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo)

  • Hiroyuki Ishiura

    (Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo)

  • Yuji Takahashi

    (Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo)

  • Jun Goto

    (Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo)

  • Jason Kost

    (Worcester Polytechnic Institute
    University of Massachusetts Medical School)

  • Cinzia Gellera

    (Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS Istituto Neurologico ‘Carlo Besta’)

  • Athina Soragia Gkazi

    (Medical Research Council Centre for Neurodegeneration Research, Institute of Psychiatry, King’s College London)

  • Jack Miller

    (Medical Research Council Centre for Neurodegeneration Research, Institute of Psychiatry, King’s College London)

  • Joanne Stockton

    (School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham)

  • William S. Brooks

    (Neuroscience Research Australia, Randwick)

  • Karyn Boundy

    (The Queen Elizabeth Hospital)

  • Meraida Polak

    (Emory University)

  • José Luis Muñoz-Blanco

    (Unidad de ELA, Instituto de Investigación Hospital Gregorio Marañón de Madrid)

  • Jesús Esteban-Pérez

    (Unidad de ELA, Instituto de Investigación Hospital 12 de Octubre de Madrid
    Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER U-723))

  • Alberto Rábano

    (Banco de Tejidos, Centro Alzheimer—Fundación Reina Sofia, Fundación CIEN)

  • Orla Hardiman

    (Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin)

  • Karen E. Morrison

    (School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham
    Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust
    Faculty of Medicine, University of Southampton)

  • Nicola Ticozzi

    (IRCCS Istituto Auxologico Italiano
    ‘Dino Ferrari’ Center—Università degli Studi di Milano)

  • Vincenzo Silani

    (IRCCS Istituto Auxologico Italiano
    ‘Dino Ferrari’ Center—Università degli Studi di Milano)

  • Jacqueline de Belleroche

    (Neurogenetics Group, Imperial College London, Hammersmith Hospital Campus)

  • Jonathan D. Glass

    (Emory University)

  • John B. J. Kwok

    (Neuroscience Research Australia, Randwick
    School of Medical Sciences, University of New South Wales, Kensington)

  • Gilles J. Guillemin

    (Faculty of Medicine and Health Sciences, Macquarie University)

  • Roger S. Chung

    (Faculty of Medicine and Health Sciences, Macquarie University)

  • Shoji Tsuji

    (Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo
    Graduate School of Medicine, The University of Tokyo)

  • Robert H. Brown

    (University of Massachusetts Medical School)

  • Alberto García-Redondo

    (Unidad de ELA, Instituto de Investigación Hospital 12 de Octubre de Madrid
    Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER U-723))

  • Rosa Rademakers

    (Mayo Clinic Florida)

  • John E. Landers

    (University of Massachusetts Medical School)

  • Aaron D. Gitler

    (Stanford University School of Medicine)

  • Guy A. Rouleau

    (Montreal Neurological Institute and Hospital, McGill University
    Montreal University)

  • Nicholas J. Cole

    (Faculty of Medicine and Health Sciences, Macquarie University
    Sydney Medical School, University of Sydney)

  • Justin J. Yerbury

    (Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong)

  • Julie D. Atkin

    (Faculty of Medicine and Health Sciences, Macquarie University
    La Trobe University)

  • Christopher E. Shaw

    (Medical Research Council Centre for Neurodegeneration Research, Institute of Psychiatry, King’s College London)

  • Garth A. Nicholson

    (Faculty of Medicine and Health Sciences, Macquarie University
    Northcott Neuroscience Laboratory, ANZAC Research Institute
    Sydney Medical School, University of Sydney
    Molecular Medicine Laboratory, Concord Hospital)

  • Ian P. Blair

    (Faculty of Medicine and Health Sciences, Macquarie University
    Northcott Neuroscience Laboratory, ANZAC Research Institute)

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping, fatal neurodegenerative disorders in which the molecular and pathogenic basis remains poorly understood. Ubiquitinated protein aggregates, of which TDP-43 is a major component, are a characteristic pathological feature of most ALS and FTD patients. Here we use genome-wide linkage analysis in a large ALS/FTD kindred to identify a novel disease locus on chromosome 16p13.3. Whole-exome sequencing identified a CCNF missense mutation at this locus. Interrogation of international cohorts identified additional novel CCNF variants in familial and sporadic ALS and FTD. Enrichment of rare protein-altering CCNF variants was evident in a large sporadic ALS replication cohort. CCNF encodes cyclin F, a component of an E3 ubiquitin–protein ligase complex (SCFCyclin F). Expression of mutant CCNF in neuronal cells caused abnormal ubiquitination and accumulation of ubiquitinated proteins, including TDP-43 and a SCFCyclin F substrate. This implicates common mechanisms, linked to protein homeostasis, underlying neuronal degeneration.

Suggested Citation

  • Kelly L. Williams & Simon Topp & Shu Yang & Bradley Smith & Jennifer A. Fifita & Sadaf T. Warraich & Katharine Y. Zhang & Natalie Farrawell & Caroline Vance & Xun Hu & Alessandra Chesi & Claire S. Leb, 2016. "CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia," Nature Communications, Nature, vol. 7(1), pages 1-8, September.
  • Handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms11253
    DOI: 10.1038/ncomms11253
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms11253
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/ncomms11253?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms11253. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.